Ranibizumab Treatment for Retinal Vein Occlusion

NCT01968616 ↗

Unknown 100 enrolled Kyoto University, Graduate School of Medicine Novartis · collab

NaSingle-groupOpen-labelTreatment

Summary

In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment have not been evaluated comprehensively. Therefore, we have planned to analyze predictors for visual outcome from a viewpoint of electrophysiology and biomarkers besides morphological features by SD-OCT.

Timeline

Start: 2013-09
Primary completion: 2019-09
Completion: 2019-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ranibizumab	Monoclonal antibody	0.5 mg	Intravitreal

Ranibizumab Treatment for Retinal Vein Occlusion

Summary

Timeline

Drugs

Indications